Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults:A retrospective observational study in Southern Italy by Guerriero, Francesca et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly
adults
Guerriero, Francesca; Orlando, Valentina; Monetti, Valeria Marina; Colaccio, Francesca
Maria; Sessa, Maurizio; Scavone, Cristina; Capuano, Annalisa; Menditto, Enrica
Published in:
Therapeutics and Clinical Risk Management
DOI:
10.2147/TCRM.S171346
Publication date:
2018
Document license:
CC BY-NC
Citation for published version (APA):
Guerriero, F., Orlando, V., Monetti, V. M., Colaccio, F. M., Sessa, M., Scavone, C., ... Menditto, E. (2018).
Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: A retrospective
observational study in Southern Italy. Therapeutics and Clinical Risk Management, 14, 1907-1914.
https://doi.org/10.2147/TCRM.S171346
Download date: 03. Feb. 2020
© 2018 Guerriero et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Therapeutics and Clinical Risk Management 2018:14 1907–1914
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1907
O R i g i n a l  R e s e a R C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/TCRM.S171346
Predictors of new oral anticoagulant drug initiation 
as opposed to warfarin in elderly adults: a 
retrospective observational study in southern italy
Francesca guerriero1,*
Valentina Orlando1,*
Valeria Marina Monetti1
Francesca Maria Colaccio2
Maurizio sessa3,4
Cristina scavone3
annalisa Capuano3,*
enrica Menditto1,*
1Center of Pharmacoeconomics 
(CiRFF), University of naples 
Federico ii, naples, italy; 2Caserta 
local health Unit, Caserta, italy; 
3Department of experimental 
Medicine, section of Pharmacology, 
Regional Center of Pharmacovigilance, 
University of Campania “l. Vanvitelli”, 
naples, italy; 4Department of Drug 
Design and Pharmacology, University 
of Copenhagen, Copenhagen, DK, 
Denmark
*These authors contributed equally 
to this work
Aim: The aim of this study was to assess the predictive role of age, gender, and number and 
type of co-treatments for new oral anticoagulant (NOAC) vs warfarin prescription in elderly 
patients naïve for the aforementioned drugs.
Materials and methods: Data collected in the period from January 1, 2014, to December 31, 
2014, in Caserta Local Health Unit administrative databases (Campania Region, Italy) were 
screened to identify new users of oral anticoagulants (OACs) who were 75 years or older and 
whose OAC prescriptions amounted to 90 days of treatment. Age, gender, and number and 
type of concomitant medications at the time of first OAC dispensation were retrieved. Multivari-
able logistic regression analysis was used to assess the role of the aforementioned predictors 
for NOAC initiation as opposed to warfarin.
Results: Overall, 2,132 incident users of OAC were identified, of whom 967 met all inclusion 
criteria. In all, 490 subjects (50.7%) received an NOAC and 477 (49.3%) received warfarin. 
Age 75 years was positively associated with lower odds of NOAC initiation (OR: 0.969, 95% 
CI: 0.941–0.998, P=0.038). Similarly, multiple concomitant medication was negatively associ-
ated with NOAC initiation compared to warfarin (OR [five to nine drugs] group: 0.607, 95% CI: 
0.432–0.852, P=0.004; OR [ten+ drugs] group: 0.372, 95% CI: 0.244–0.567, P0.001). Prior 
exposure to platelet aggregation inhibitor drugs was associated with the initiation of NOACs 
(OR: 3.474, 95% CI: 2.610–4.625).
Conclusion: Age and multiple co-medication were negatively associated with NOAC 
initiation.
Keywords: retrospective databases, real-world data, atrial fibrillation, oral anticoagulation, 
drug utilization
Introduction
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, and its prevalence 
increased progressively with age.1–3 AF prevalence was estimated to be less than 
0.1% in the population aged 55 years and rise to over 8% in those aged 80 years.4 
Patients with AF have a fivefold higher risk of stroke, which increases with age, 
reaching 23.5% between 80 and 89 years of age.5 Vitamin K antagonists (VKAs) 
have been historically used to reduce cardiovascular risk associated with AF espe-
cially for stroke prophylaxis.6 However, recently, a new therapeutic alternative to 
VKA was introduced, the new oral anticoagulants (NOACs). NOACs include both 
direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (rivaroxaban, 
apixaban, and edoxaban). Dabigatran and rivaroxaban were authorized by European 
Medicine Agency (EMA) in 2008 and became available on the Italian market in 2013. 
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Apixaban was approved by EMA in 2011 and became avail-
able for use in clinical practice in Italy in January 2014, while 
edoxaban was the last NOAC that obtained the marketing 
authorization by EMA in June 2015. Initially, in 2010, the 
Italian Medicine Agency (Agenzia Italiana del Farmaco, 
AIFA) allowed the use of NOACs only for the prophy-
laxis of venous thromboembolism after hip replacement 
surgery and knee surgery. However, since 2013, AIFA has 
extended the authorization also for reducing cardiovascular 
risk in non-valvular AF. In terms of stroke and systemic 
thromboembolism prevention, dabigatran, apixaban, rivar-
oxaban, and edoxaban demonstrated at least non-inferiority 
to warfarin.7 Moreover, NOACs, when compared to VKA, 
provided a more reliable anticoagulation effect with a 
limited drug–drug and drug–food interactions, especially 
in frail population, such as elderly patients.8,9 Considering 
these advantages, European guidelines for the management 
of AF recommended the initiation of an NOAC instead of 
warfarin in non-valvular AF.7 However, to date, previous 
studies suggested that VKA tends to be underutilized espe-
cially in the elderly patients with AF.10 Considering that 
little is known on the widespread activity of NOACs as 
therapeutic alternative in patients with AF, and even less is 
known on the predictors leading to their choice in clinical 
practice, this study aimed to fill this gap by investigating the 
use of NOACs and predictors of its initiation, as opposed to 
warfarin, in elderly patients with AF.
Materials and methods
Data source
Based on data availability, we retrieved anonymized data 
stored in Caserta Local Health Unit (LHU) administrative 
databases from January 1, 2014, to December 31, 2014. For 
reimbursement purposes, Caserta LHU administrative data-
bases contain demographical information (ie, age, gender, 
and date of death), hospital contact, and drugs redeemed/
supplied from pharmacies/local health authority in the 
catchment area of Caserta (Campania Region, Italy) which 
covers a population of approximately 1 million inhabitants. 
For each redeemed/supplied prescription information on the 
active ingredient, dose, formulation, the number of packages, 
the date of dispensation, drug price, and the Anatomical 
Therapeutic Chemical (ATC) classification system code were 
available.11 In the aforementioned databases, all informa-
tion was linked through a unique and anonymous personal 
identification code. These data sources have been previously 
used for pharmacoepidemiological and drug utilization study 
purposes.12–19
study population
The study population consisted of all subjects aged 75 years 
or older receiving at least one prescription of warfarin or 
NOAC in the period from January 1, 2014, to December 31, 
2014. We defined a subject as receiving a warfarin prescrip-
tion if he/she redeemed a prescription with a drug having 
ATC code B01AA03. On the other hand, we defined NOAC 
users as those subjects redeeming prescriptions of dabigatran 
(ATC code: B01AE07), rivaroxaban (ATC code: B01AF01), 
and apixaban (ATC code: B01AF02). The date of the first 
redemption of such prescriptions was used as the index 
date for each subject. From this preliminary population, we 
identified our study population that is composed of naïve users 
of warfarin or NOACs. We defined a subject as naïve for 
warfarin or NOACs if he/she did not redeem prescriptions 
of these drugs within 365 days prior to index date. Because 
information on the medical needs leading to a prescription of 
warfarin or NOACs was not available, to assume AF as the 
indication of use for such drugs, we restricted the analysis to 
subjects whose pharmacy prescriptions amounted to 90 days 
of anticoagulation (90 or more days between first and last 
OAC prescription dates). Figure 1 shows the flowchart of 
the study.
study covariates
For each subject, we retrieved information on age, gender, and 
co-treatment in the 12-month period prior to the index date. 
Specifically, we evaluated the number of co-prescribed medi-
cations within 365 days prior to index date and the exposure 
to specific co-treatments: drugs platelet aggregation inhibitor 
(PAI) excluding heparin (ATC: B01AC), anti-inflammatory 
and antirheumatic products (ATC: M01A), and proton pump 
inhibitor (PPI; ATC: A02B). Moreover, AF drugs such as 
digitalis glycosides (ATC: C01AA), antiarrhythmics class Ia 
(ATC: C01BA), antiarrhythmics class Ic (ATC: C01BC), 
antiarrhythmics class III (ATC: C01BD), strophanthus 
glycosides (ATC: C01AC), other cardiac glycosides (ATC: 
C01AX), nonselective beta-blocking agents (ATC: C07AA), 
selective beta-blocking agents (ATC: C07AB), and alpha and 
beta-blocking agents (ATC: C07AG) were also evaluated. 
Finally, selective serotonin reuptake inhibitor/serotonin 
norepinephrine reuptake inhibitor (SSRI/SNRI; ATC: N06A) 
was evaluated. The number of co-prescribed drugs was cat-
egorized as follows: 0–4 drugs, 5–9 drugs, and 10 drugs.
Outcomes
The study outcomes are the OR of receiving an NOAC 
prescription as opposed to a warfarin prescription among 
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genders, ages (expressed as unitary increase), and patients 
exposed to specific co-treatments.
statistical analysis
Baseline characteristics of the study cohort were presented 
separately for NOACs and warfarin. Continuous variables 
were presented as mean ± SD, and differences between two 
therapy groups were compared using the Student’s unpaired 
t-test. Categorical variables were presented as numbers 
(percentages) and were compared across therapy groups 
by chi-squared test. Univariate and multivariate logistic 
regression models were conducted to identify whether study 
covariates were predictors of NOAC initiation as opposed 
to warfarin. In the multivariate model, all the potential pre-
dictors were entered that were significant at the P0.25 in 
the univariate analysis. All analyses were performed using 
SPSS software version 17.1 for Windows (IBM Corporation, 
Armonk, NY, USA). A P-value of 0.05 was considered as 
statistical significance.
Results
Overall, 4,392 subjects aged 75 years or older, with at 
least one prescription of OAC drugs, were identified from 
January 1, 2014, to December 31, 2014. Among these 
subjects, 967 out of 4,392 (22.01%) were naïve and treated 
for at least 90 days with OACs (Figure 1). The characteristics 
of the study population are summarized in Table 1. The mean 
age (SD) of the study population was 81.5 years (4.5 years), 
and the female gender (61.4%) was predominant. In all, 
490 (50.7%) out of the 967 patients were exposed to NOACs 
and 477 (49.3%) to warfarin. Among the 490 patients treated 
with NOACs, more than half (58.6%) received rivaroxaban, 
22.4% apixaban, and 19.0% dabigatran. A significantly 
lower number of subjects received PAI among warfarin 
users if compared to NOAC users (P0.001). The number 
of patients receiving AF drugs, NSAIDs, and SSRI/SNRI 
was comparable between patients exposed to NOAC therapy 
vs those exposed to warfarin. The number of co-prescribed 
drugs was comparable between NOAC and warfarin patients 
(P=0.076).
Predictors of nOaC initiation
Increasing age was significantly associated with a lower odds 
of NOAC initiation: for each 1-year increase in age, patients 
were about 3% less likely to receive an NOAC (OR: 0.969, 
95% CI: 0.941–0.998, P=0.038; Table 2 and Figure 2). As the 
number of co-prescribed medicines increased, an increased 
likelihood of receiving warfarin as opposed to NOACs was 
observed. In particular, subjects exposed to five to nine drugs 
and those exposed to ten+ drugs were 39% and 63% less 
likely to receive an NOAC (OR [five to nine drugs] group: 
0.607, 95% CI: 0.432–0.852, P=0.004; OR [ten+ drugs] 
group: 0.372, 95% CI: 0.244–0.567, P0.001). The strongest 
predictors of NOAC initiation were the previous exposure to 
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
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Figure 1 Patient selection flowchart.
Abbreviations: nOaCs, new oral anticoagulants; OaCs, oral anticoagulants.
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PAI which was three times more likely to use an NOAC as 
opposed to warfarin (OR: 3.474, 95% CI: 2.610–4.625).
Ethics statement
All procedures performed in this study were in accor-
dance with the current national law from Italian Medicines 
Agency.45 The manuscript does not contain clinical studies, 
and all patients’ data were fully anonymized. For this type 
of study, formal consent is not required. Permission to use 
anonymized data for the present study was granted by the 
responsible authority, Caserta LHU, Regione Campania.
Discussion
This study provides up-to-date information on the recent anti-
coagulation prescription behavior in elderly patients with AF 
in the catchment area of Caserta (Campania Region, Italy). In 
this regard, it should be emphasized that stroke prophylaxis 
among high-risk patients, eg, elderly, is clinically challeng-
ing, and data show that OAC treatment is often underused.20,21 
The suboptimal OAC treatment of elderly patients has been 
increasingly explored in recent years as elderly patients are at 
particularly high risk of stroke, and prior studies have shown 
that OAC provides a net clinical benefit among elderly AF 
patients.22,24 According to our findings, polypharmacy seems 
to drive the choice of VKA over NOAC. In fact, elderly 
patients with AF exposed to moderate polypharmacy (five to 
nine drugs) and extensive polypharmacy (ten+ drugs) were 
39% and 63% less likely to receive an NOAC compared 
to warfarin users, respectively. This finding is in line with 
a retrospective study carried out in Ireland showing that 
Table 1 Descriptive statistics of the study population (n=967)
NOACs (n=490) Warfarin (n=477) Overall (N=967) P-value
gender (female) 289 (59.0%) 305 (63.9%) 594 (61.4%) 0.113
age (mean ± sD) 81.3±4.5 81.6±4.5 81.5±4.5 0.217
age group 0.517
75–79 years 193 (39.4%) 177 (37.1%) 370 (38.3%)
80–84 years 176 (35.9%) 167 (35.0%) 343 (35.5%)
85+ years 121 (24.7%) 133 (27.9%) 254 (26.3%)
Receiving Pai 273 (55.7%) 150 (31.4%) 423 (43.7%) 0.001*
Receiving aF drugs 378 (77.1%) 372 (78.0%) 750 (77.6%) 0.753
Receiving nsaiDs 221 (45.1%) 220 (46.1%) 441 (45.6%) 0.750
Receiving J02a 15 (3.1%) 13 (2.7%) 28 (2.9%) 0.755
Receiving PPi 369 (75.3%) 367 (76.9%) 736 (76.1%) 0.552
Receiving ssRi/snRi 74 (15.1%) 72 (15.1%) 146 (15.1%) 0.997
number of co-prescribed medicines 0.076
0–4 118 (24.1%) 92 (19.3%) 210 (21.7%)
5–9 272 (55.5%) 264 (55.3%) 536 (55.4%)
10–14 100 (20.4%) 121 (25.4%) 221 (22.9%)
Note: *P-value of 0.05 was considered statistically significant.
Abbreviations: AF, atrial fibrillation; J02A, antimycotics for systemic use; NOACs, new oral anticoagulants; PAI, platelet aggregation inhibitor; PPI, proton pump inhibitor; 
ssRi/snRi, selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor.
Table 2 Univariate and multivariate model predicting the initiation of nOaCs vs warfarin
Characteristics Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
sex
Male Reference Reference
Female 0.811 (0.626–1.051) 0.113 0.830 (0.631–1.090) 0.180
age (years) 0.982 (0.955–1.010) 0.217 0.969 (0.941–0.998) 0.038*
Receiving Pai
no Reference Reference
Yes 0.365 (0.280–0.474) 0.001* 3.474 (2.610–4.625) 0.001*
number of co-prescribed medicines
0–4 Reference Reference
5–9 0.803 (0.583–1.107) 0.181 0.607 (0.432–0.852) 0.004*
10+ 0.644 (0.441–0.942) 0.023* 0.372 (0.244–0.567) 0.001*
Notes: OR values higher than 1.0 indicate predictors of nOaC initiation as opposed to warfarin and vice versa. *P-value of 0.05 was considered statistically significant.
Abbreviations: nOaCs, new oral anticoagulants; Pai, platelet aggregation inhibitor.
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multiple concomitant medications were negatively associ-
ated with NOAC initiation.25 On the other hand, our findings 
are in contrast with other previous studies. Results of the 
study by Belen et al,26 which investigated the reasons for 
a decline in VKA utilization, revealed that potential drug–
drug interactions (DDIs) and diet were the most common 
reasons for choosing NOAC over VKA. According to Belen 
et al, further literature data demonstrated that, especially for 
elderly patients, NOACs represent a more suitable treatment 
option compared to warfarin due to a more predictable dos-
ing, fewer DDIs, and reduced risk of intra cranial bleeding.27 
In addition, a study by AbuDagga et al28 reported that older 
age decreased the probability of initiating dabigatran, but 
their study ended in 2014, and rivaroxaban and apixaban 
data were absent. Nevertheless, our results showed that 
VKA treatment is still used and, in contrast to the NOACs, 
VKAs have the advantage of being suitable for patients with 
severe renal impairment (creatinine clearance 15 mL/
min).22 Still, a lack of knowledge on NOACs’ DDIs may 
limit their tangible use, especially in elderly patients. As 
a matter of fact, despite their advantages over warfarin, 
NOACs carry a potential for DDIs, which could occur more 
frequently in elderly than in younger patients, due to the 
age-related higher prevalence of comorbidities and poly-
medication.29 A recent review by Stöllberger30 highlighted 
that several drugs, including acetylsalicylic acid, clopi-
dogrel, ticagrelor, prasugrel, NSAIDs, and SSRIs/SNRIs, 
could interact with NOACs, increasing the risk of bleeding 
complications. Moreover, since NOACs are metabolized 
by the CYP/CYP450 isoenzymes 3A4 (CYP3A4) and 2J9 
(CYP2J9), DDIs were also identified with drugs that affect 
the activity of such cytochrome isoenzymes. Furthermore, 
considering that NOACs are substrates for the drug ellux 
pump, P-glycoprotein (P-gp),drugs affecting the activity of 
P-gp, such as atorvastatin, clarithromycin, and diltiazem, can 
increase the risk of bleeding, thromboembolism, and further 
adverse events. Finally, it was found out that NOACs could 
influence the serum and tissue concentrations of immuno-
suppressant and analgesic drugs as well as that PPIs may 
affect NOAC bioavailability changing the gastric pH. 
A recent retrospective cohort study, which has evaluated, 
on more than 90,000 patients, the effects on major bleedings 
of co-exposure to NOACs and other drugs, revealed that 
the concurrent use of NOACs and amiodarone, fluconazole, 
rifampin, and phenytoin was associated with the increased 
risk of the main outcome.31 However, considering that few 
Favors warfarin Favors NOACs
OR 0.83 (0.63–1.09)
OR 0.97 (0.94–0.99)
OR 3.47 (2.61–4.62)
OR 0.60 (0.43–0.85)
OR 0.37 (0.24–0.56)
Sex (female) (Ref=(male))
Age  
Co-prescribed medicine (5–9) (Ref=(0–4))
Co-prescribed medicine (=10) (Ref=(0–4))
Receiving PAI  
OR (95% CI)
10.5 2
Figure 2 Forest plot of predictors of nOaC vs warfarin initiation.
Abbreviations: nOaCs, new oral anticoagulants; Pai, platelet aggregation inhibitor; Ref, reference.
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data from clinical practice are nowadays available on this 
topic, further data are strongly needed. Another interesting 
finding of our study is that the factor most strongly associated 
with NOAC initiation was the previous PAI utilization. In 
particular, patients receiving PAI medication were more than 
three times as likely to use an NOAC compared to warfarin 
(OR: 3.474, 95% CI: 2.610–4.625). These results could be 
explained considering that the concomitant use of PAI and 
OACs, also known as triple oral antithrombotic therapy 
(TOAT), is required in the specific group of patients affected 
by cardiovascular disease, usually AF which had drug-eluting 
stent implantation or acute coronary syndrome.32 Therefore, 
in our opinion, the higher probability for patients receiving 
PAI medication to initiate an NOAC could be related to 
the easier management of therapy with NOAC compared 
to warfarin especially in terms of its bleeding risk. In our 
cohort, more than 50% of patients received a prescription of 
rivaroxaban, 22% of elderly patients were on apixaban, while 
dabigatran was adopted in about 19% of elderly patients. In 
this regard, we do not believe that this result could be asso-
ciated with the different efficacy/safety differences among 
NOACs. In fact, the pivotal study for rivaroxaban, the multi-
center, randomized, double-blind, double-dummy ROCKET 
AF trial, which compared once-daily oral rivaroxaban with 
dose-adjusted warfarin for the prevention of stroke and sys-
temic embolism in patients with nonvascular AF who were 
at moderate to high risk for stroke, revealed that rivaroxaban 
was non-inferior to warfarin, with an annual rate of stroke 
and systemic embolism 2.12% vs 2.42% (P0.001) reported 
with warfarin.7 Safety results demonstrated that rivaroxaban 
was associated with a significant reduction in fatal bleeding 
(0.2% vs 0.5% per year, P=0.003) and cerebral hemorrhage 
(0.5% vs 0.7% per year, P=0.02). Since rivaroxaban is, for 
one-third, renally cleared, it is especially safe in patients with 
mild renal impairment (creatinine clearance 30–49 mL/min), 
which is one of the most frequent comorbidities in the 
elderly.33 Similarly, the results of ARISTOTLE trial and its 
post hoc analyses found that apixaban had a lower relative 
risk of stroke or systemic embolism as well as major bleeding 
and death when compared to warfarin.34,35 Moreover, a recent 
review by Diener et al36 suggested apixaban as the first choice 
in AF patients older than 75 years. Although no comparable 
head-to-head randomized trial has examined the efficacy and 
safety between the NOACs yet, it is likely that the positive 
results from the ARISTOTLE trial might have influenced the 
rapidly increased uptake of apixaban compared to the other 
NOACs, in particular among elderly AF patients.37 Finally, 
dabigatran was also associated with a notably lower relative 
risk of stroke or systemic embolism compared to warfarin, 
although it was related to an increased risk of gastrointestinal 
bleedings.38 Notably, approximately 80% of dabigatran is 
eliminated by renal clearance, and a condition with impaired 
renal function is often found among elderly patients.39 Data 
from the RE-LY trial showed that renal function was highly 
correlated with age, and plasma concentration of dabigatran 
increased with advancing age.40
Local policies should provide training and information 
to health care professionals to optimize health resources also 
implementing successful elements from other EU countries’ 
activities.41,42 Synergies between different actors involved in 
health care delivery can help achieve better results. Further 
studies are needed to improve our knowledge of the safety 
profile in a real-world setting.
strengths and limitations
The main strength of our study is based on a data source with 
full coverage of the warfarin and NOAC prescriptions for a 
geographically defined, stable population, and we were able 
to account for multiple confounders such as age, gender, and 
co-medications.10 However, the study also has potential limita-
tions. Some predictive factors, such as comorbidities or previous 
cardiovascular events, have not been considered. Furthermore, 
as VKA administration may increase arterial stiffness (which 
is a predictor of cardiovascular risk), lack of information about 
diagnosis and stroke occurrence did not allow us to evaluate 
the advantage of NOAC use vs warfarin. Data reported in the 
study refer to 2014, and the current patterns regarding the use 
of NOACs could have changed meanwhile. Finally, doses of 
NOACs used have not been reported: further studies should be 
carried out for evaluating dosing regimens used in the real prac-
tice as reduced doses could be inappropriate and ineffective.
Conclusion
This study provides data on prescription of NOACs and 
warfarin from clinical practice in the Italian national terri-
tory. In a real-world setting, multiple co-medication may be 
associated with lower likelihood of NOAC initiation. This 
trend is more evident in patients with excessive polyphar-
macy (more than ten drugs) bringing significant implications 
for cost-effectiveness and outcome studies.
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